+ Watch DVAX
on My Watchlist
A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.
In July 2011 Dynavax reported topline results from the HBV-16 phase III trial of their Hepatitis B vaccine Heplisav in adults aged 40-70. They found that two doses of Heplisav administered one month apart conferred 90% seroprotection 8 weeks after the last dose and 92% seroprotection 52 weeks after the first dose, while standard of care vaccine Engerix-B conferred 70% seroprotection 8 weeks after the last dose and 59% seroprotection 52 weeks after the first dose.Despite this seemingly indisputable efficacy benefit for Heplisav, the share price actually dropped significantly after the results were released for three reasons:1. The company reported that the Heplisav group did not meet pre-specified consistency criteria for antibody production after 8 weeks, thereby technically failing the primary endpoint.2. Three new onset autoimmune events occurred in the Heplisav group and none occurred in the Engerix group. The company claimed this could be attributed to chance given the 4:1 randomization of patients to Heplisav vs Engerix.3. Many traders sold on the news as Dynavax stock had risen dramatically from 2008 lows and the commercial prospects for Heplisav seemed questionable at that time.The share price did rebound after the company reassured investors that according to FDA standards, consistency criteria were met. However, ongoing nervousness about Heplisav's revenue potential resulted in a severe downturn during the broad market instability of late 2011 and a low of 1.82. This, as it turns out, was a very good time to buy and I came close to capturing the low with a green thumb here http://caps.fool.com/Pitch/DVAX/5983252/dynavax-rose-as-high-as-316-in.aspx , but I felt the stock was too risky for real money. From October 2011 to May 2012 the share price nearly tripled to a high of 5.26. Only another monster dilutive financing of 70M was able to dampen the upward momentum.I have to admit I'm still very confused about what happened to Heplisav in late 2011 and early 2012, and went deep into negative points territory with my red thumb http://caps.fool.com/Pitch/DVAX/6118083/i-recently-did-well-on-a-green.aspx I based my long-term pessimistic view of Dynavax on the results of the PHAST phase III trial of Heplisav in 2008. After the FDA severely restricted the potential population for Heplisav in 2008 due to a single case of Wegener's granulomatosis in a test subject, the share price dropped as low as 0.16 and Merck terminated the partnership on Heplisav. It is possible that the only thing that saved Dynavax from the 2008 lows was the announcement of an unrelated partnership with GSK to develop inhibitors of Toll-like receptors for inflammatory diseases. This announcement resulted in a six-fold increase in share price and gave the company enough strength to restore their cash runway through dilution. Dynavax has subsequently gone on to take liberal advantage of the capital markets through private placements and ATM's, such that their common share count has ballooned from 55M in May 2010 to 179M as of the last quarterly statement. Dynavax's appreciation in share price was dwarfed by their appreciation in market cap.In September 2009 the FDA lifted the clinical hold on Heplisav and Dynavax initiated a new phase III trial of Heplisav in patients with chronic kidney disease, as the FDA had indicated that Heplisav might have an acceptable risk/benefit profile in this subpopulation. The company initiated the HBV-16 trial in early 2010 as a "lot-to-lot consistency trial" which was also intended to expand the safety database. While this was not initially portrayed as a registrational efficacy trial, it appears that Dynavax used it as a Trojan Horse to sneak another phase III efficacy trial for general population past the FDA despite the previous clinical hold.Subsequent to the latest phase III trial results, Dynavax announced their intention to submit an initial BLA for the general population of adults over 40, followed by a supplemental BLA for chronic kidney disease patients after the initial BLA was approved. This plan came despite what appeared to be a drastic and uncompromising view by the FDA in 2008 that Heplisav had an unacceptable risk/benefit profile except for specific hyporesponding subsets. Then in February 2012 Dynavax announced after a pre-BLA meeting with the FDA that the Heplisav submission would be expanded to adults aged 18-70. It now appeared that the FDA had completely retraced their position on Heplisav safety, abandoning all prior restrictions to Heplisav usage.Fast forward to November 2012 and the FDA Advisory Committee meeting on Heplisav. Based on the buzz from the street, it seemed that any prior FDA concerns about autoimmune adverse events were forgotten and a strongly positive vote was practically a foregone conclusion. Never mind the 2008 clinical hold, never mind the prior drastic restriction on Heplisav usage handed down by the FDA, never mind the dramatic dilution Dynavax utilized to build a huge 160M war chest ahead of the meeting. Of course, it turned out that these were all warnings to dump the position ahead of an eventual 8-5 committee vote that Dynavax had not convincingly demonstrated Heplisav's safety.The vote decimated the share price and was a great pick in after hours with a low around 1.7. The degree of the drop was excessive considering that a lot of large funds and institutions are now deeply underwater on the trade and will be working overtime to push the share price back up prior to the PDUFA on 2/24/13. We'll be hearing a lot between now and the PDUFA about how the FDA briefing documents didn't raise concerns about adverse autoimmune events, and how the Ad Comm chairman was conflicted by ties to GSK (maker of Engerix), and various other reasons why Heplisav will get first pass FDA approval.Personally, I wouldn't bet on it. Heplisav represents a nice upgrade to the current array of hep B vaccines but it's far from indispensable. Historic measurements of seroprotection by Engerix B and Recombivax-HB are substantially better than the findings in Dynavax's trials.http://adisonline.com/drugs/Abstract/2003/63100/Recombinant_Hepatitis_B_Vaccine__Engerix_B_R____A.6.aspx I think it's very unlikely that the FDA will go against a safety recommendation from their own Advisory Committee for a solution to a problem (hep B vaccine efficacy) that may not even exist. Dynavax has already enjoyed a substantial rebound from the lows after the Ad Comm vote and is likely to move even higher before the PDUFA. But if you're underwater on this stub I wouldn't cross my fingers and hold through the PDUFA. This time, head for the lifeboat.
I'm so happy with my 2012 self right now for taking the time to sit down and write this long and detailed pitch instead of doing something fun. The pitch was probably my most valuable reference when I made the decision to buy 5000 shares of Dynavax at 3.04 today ahead of the Heplisav PDUFA on February 24. If I make money on the trade, it's a nice validation of the way I currently use CAPS to record the evolution of my mindset on stocks over time. If I lose money, my 2012 self should just go screw himself.I'm very surprised that no one is talking about Dynavax on Twitter or Seeking Alpha. After all, it was just a few months ago that a negative Ad Comm safety vote defied market expectations and crushed the stock. The stock rebounded to some degree shortly after that event but nowhere close to the peak of 5 seen before the Ad Comm. However, the market cap is a hefty 538M backed by 148M in cash and an early stage pipeline of TLR compounds behind Heplisav. I see the share price hitting 5 or maybe 6 with Heplisav approval and dropping below 1.5 with rejection.The arguments as I see them for approval are as follows:1. FDA briefing documents did not highlight safety concerns.2. Ad Comm safety vote was only 8-5 against and possibly colored by conflict of interest.3. Heplisav represents a significant upgrade over SOC with regard to efficacy and logistics.The arguments for rejection:1. I cannot recall any FDA approvals that went against Ad Comm safety votes. Anyone?2. As delineated in my outperform pitch, the pathway to the Heplisav BLA submission for unrestricted use was very convoluted and contradictory.3. Heplisav is not meeting any urgent medical need due to the existence of an adequate SOC.Either way, I think Dynavax could see some upward momentum in a fairly quiet month of February for small cap biopharma. It's the next PDUFA and there aren't even any Ad Comm's before then. People are going to be hungry for catalysts. Options seem relatively low priced to me, with the ask on March 4 calls at 40 cents and the ask on March 2.5 puts at 45 cents. I may double my long bet later in the week. I don't plan to be long through the PDUFA but I may roll any profits into calls or an options spread. One risk with options is the possibility of approval with a restricted label which could cause the stock to trade flat.
Just added another 5000 shares at 3.18 for a total of 10000 in portfolio (non-GBMB) at a cost basis of 3.11.
Just bought 20 contracts of the March 2.5 calls at 0.95.
Just bought another 10000 shares at 1.86 to give me a total of 20000 at a cost basis of 2.485. Hopefully it is moving to the low end of a range and not flushing.
Just sold 10000 shares at 2.08 for a loss of $4050. Still have 10000 shares at a cost basis of 2.485. Looks like doubling down was the right move.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions